TY - JOUR T1 - Estimating the risk of hospitalisation and death in England’s remaining unvaccinated population JF - medRxiv DO - 10.1101/2022.04.13.22272869 SP - 2022.04.13.22272869 AU - Joseph Shingleton AU - Steven Dyke AU - Archie Herrick AU - Brodie Walker AU - Thomas Finnie Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/19/2022.04.13.22272869.abstract N2 - The roll-out of COVID-19 vaccines in the England has generally been very good – with over 80% of over 12s having received two doses of vaccine by the start of February 2022, and 67% having received a further booster dose. Despite this, there is a small section of the population who remain unvaccinated, either due to lack of access, hesitancy or resistant to vaccination. In this report we estimate that, during 2021, there were approximately 3,500 deaths in unvaccinated people, who could otherwise have reasonably been expected to receive a vaccination. Further, we show that if all of the remaining unvaccinated population in England were to become infected (or reinfected) with the Omicron variant of COVID-19, we would expect to see approximately 11,700 further deaths and 29,600 hospitalisations. These number could fall to 5,300 and 19,600 respectively, if all but the most vaccine resistant individuals become fully vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded through Department of Heath and Social Care grant in aid funding to UK Health Security Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work is exempt from ethical clearance. UK Health Security Agency has legal permission under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 (United Kingdom), to conduct national surveillance of communicable diseases in England and, as such, individual patient consent is not required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome of the data used in this study are not available publicly. Where data are publicly available, links to the relevant sources are included in the bibliography. All data produced by the study are contained within the manuscript. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1049160/Vaccine-surveillance-report-week-3-2022.pdf https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/ ER -